You are here

Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)

Last updated on February 23, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gram-Positive Bacterial Infections, Staphylococcus Infections, Vancomycin Resistance, Methicillin Resistance
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female subjects aged 18 years or older

- Isolation of one of the following multi-antibiotic resistant bacteria:
vancomycin-resistant Enterococcus faecium, vancomycin-resistant Enterococcus faecalis,
or methicillin-resistant Staphylococcus aureus, alone or as part of a polymicrobial
infection

- Have a confirmed diagnosis of a serious infection (eg, bacteremia [unless due to an
excluded infection], complicated intra-abdominal infection, complicated skin and skin
structure infection, or pneumonia) requiring administration of intravenous (IV)
antibiotic therapy

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with any concomitant condition or taking any concomitant medication that, in
the opinion of the investigator, could preclude an evaluation of a response or make it
unlikely that the contemplated course of therapy or follow-up assessment will be
completed or that will substantially increase the risk associated with the subject's
participation in this study

- Anticipated length of antibiotic therapy less than 7 days

- For subjects with VRE, known or suspected hypersensitivity to tigecycline or
linezolid, or other compounds related to these classes of antibacterial agents (eg,
oxazolidinones, tetracyclines, minocycline, doxycycline). For subjects with MRSA,
known or suspected hypersensitivity to tigecycline or vancomycin, or other compounds
related to these classes of antibacterial agents (eg, tetracyclines, minocycline,
doxycycline)

NCT00079976
Pfizer
Completed
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Gram-Positive Bacterial Infections, Staphylococcus Infections, Vancomycin Resistance, Methicillin Resistance
NCT00079976
All Genders
Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections
NCT00167999
All Genders
15+
Years
Seoul,
Gram-Positive Bacterial Infections
NCT00167960
All Genders
18+
Years
Multiple Sites
Gram-Positive Bacterial Infections, Cross Infection
NCT00081744
All Genders

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now